• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国按年龄组划分的前列腺特异性抗原检测的全国范围内发病率趋势:十年间的变化

The national-wide incidence of prostate-specific antigen testing trend for a decade in Korea by age group.

机构信息

Department of Urology, College of Medicine, Yeungnam University, Daegu, Korea.

Medical R&D Service Design Center, College of Medicine, Yeungnam University, Daegu, Korea.

出版信息

Investig Clin Urol. 2022 Mar;63(2):184-191. doi: 10.4111/icu.20210463.

DOI:10.4111/icu.20210463
PMID:35244992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8902428/
Abstract

PURPOSE

To document nationwide serum prostate-specific antigen (PSA) testing trends over the past decade and to investigate the impact of testing on prostate cancer (PCa) detection.

MATERIALS AND METHODS

Using annual National Health Insurance Service of Korea data for the period 2006 to 2016, PSA testing rates were investigated for men aged ≥40 years by decade, and associations between test rates and registered PCa cases were analyzed.

RESULTS

During the study period, the incidence of PCa increased about threefold (4,415 in 2006 to 15,046 in 2016). PCa incidences increased with age (p<0.001) and about 60% of cases were over 70 years old. Despite a fourfold increase in PSA testing (246,911 in 2006 to 937,548 in 2016), the average exposure rate among all men was only 7.27% in 2016, and the mean number of repeat tests for those that did not develop PCa during the study period was 2.9. PSA test rates increased with age and in 2016 were 1.65% for those in their 40s, 4.90% for those in their 50s, 12.0% for those in their 60s, 19.2% for those in their 70s, and 21.6% for those aged ≥80. Regardless of the age groups, a significant association was found between PSA test numbers and the detection of PCas.

CONCLUSIONS

In contrast to the soaring incidence of PCa especially in those aged over 70 years who have a more frequent chance for PSA testing triggered by concomitant voiding symptoms, low exposure in general and among relatively younger men favors a countrywide screening policy.

摘要

目的

记录过去十年全国范围内血清前列腺特异性抗原(PSA)检测趋势,并研究检测对前列腺癌(PCa)检出率的影响。

材料与方法

利用韩国国家健康保险服务 2006 年至 2016 年期间的年度数据,按十年为一个阶段,调查≥40 岁男性的 PSA 检测率,并分析检测率与登记 PCa 病例之间的关系。

结果

在研究期间,PCa 的发病率增加了约三倍(2006 年为 4415 例,2016 年为 15046 例)。PCa 的发病率随年龄增长而增加(p<0.001),约 60%的病例年龄超过 70 岁。尽管 PSA 检测量增加了四倍(2006 年为 246911 次,2016 年为 937548 次),但 2016 年所有男性的平均暴露率仅为 7.27%,在研究期间未发生 PCa 的男性平均重复检测次数为 2.9 次。PSA 检测率随年龄增长而增加,2016 年 40 多岁人群的检测率为 1.65%,50 多岁人群的检测率为 4.90%,60 多岁人群的检测率为 12.0%,70 多岁人群的检测率为 19.2%,80 岁及以上人群的检测率为 21.6%。无论年龄组如何,PSA 检测次数与 PCa 的检出率均呈显著相关。

结论

与 70 岁以上人群 PCa 发病率飙升形成鲜明对比的是,这些人群由于伴随排尿症状而更频繁地进行 PSA 检测,导致发病率升高,而总体上以及相对年轻男性中的低暴露率有利于全国范围内的筛查政策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/decf/8902428/48d21638e2cd/icu-63-184-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/decf/8902428/c2037bc0ae79/icu-63-184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/decf/8902428/48d21638e2cd/icu-63-184-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/decf/8902428/c2037bc0ae79/icu-63-184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/decf/8902428/48d21638e2cd/icu-63-184-g002.jpg

相似文献

1
The national-wide incidence of prostate-specific antigen testing trend for a decade in Korea by age group.韩国按年龄组划分的前列腺特异性抗原检测的全国范围内发病率趋势:十年间的变化
Investig Clin Urol. 2022 Mar;63(2):184-191. doi: 10.4111/icu.20210463.
2
The Short- and Long-Term Anticipation of Prostate Cancer Incidence in Korea: Based on Social Aging Trends and Prostate-Specific Antigen Testing Rate during the Last Decade.韩国前列腺癌发病率的短期和长期预测:基于过去十年的社会老龄化趋势和前列腺特异性抗原检测率
Cancers (Basel). 2024 Jan 24;16(3):503. doi: 10.3390/cancers16030503.
3
Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study.在一个社会对前列腺癌认知有限的国家,重复前列腺特异性抗原筛查对治疗模式的影响:韩国全国观察性研究。
Investig Clin Urol. 2021 May;62(3):282-289. doi: 10.4111/icu.20200302. Epub 2021 Mar 29.
4
Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.基于人群的澳大利亚年轻男性(<55 岁)前列腺特异性抗原(PSA)筛查分析。
BJU Int. 2014 Jan;113(1):77-83. doi: 10.1111/bju.12354. Epub 2013 Oct 31.
5
Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines.爱尔兰前列腺特异性抗原检测趋势:无指南国家的经验教训。
Ir J Med Sci. 2010 Mar;179(1):43-9. doi: 10.1007/s11845-009-0376-7. Epub 2009 Jun 27.
6
Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.美国转移性前列腺癌的过去、现在和未来发病率及负担。
Eur Urol Focus. 2018 Jan;4(1):121-127. doi: 10.1016/j.euf.2017.10.014. Epub 2017 Nov 20.
7
The Impact of Prostate-Specific Antigen Screening on Prostate Cancer Incidence and Mortality in China: 13-Year Prospective Population-Based Cohort Study.前列腺特异性抗原筛查对中国前列腺癌发病率和死亡率的影响:基于人群的13年前瞻性队列研究
JMIR Public Health Surveill. 2024 Jan 18;10:e47161. doi: 10.2196/47161.
8
Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.在前列腺癌筛查中使用低游离 PSA 与总 PSA 比值:血清 PSA 水平<4.0ng/mL 的巴西男性中的检出率、临床和病理发现。
BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.
9
Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?前列腺癌的前列腺特异性抗原检测:是否会耗尽有限的易感个体群体?
Eur J Epidemiol. 2017 Jun;32(6):511-520. doi: 10.1007/s10654-016-0185-z. Epub 2016 Jul 18.
10
Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.关于前列腺特异性抗原检测,指南与临床实践之间存在差异。
Fam Pract. 2013 Dec;30(6):648-54. doi: 10.1093/fampra/cmt045. Epub 2013 Oct 9.

引用本文的文献

1
Determinants of Prostate Cancer Screening in Korean Men: A Nationwide Study Using the Korean National Cancer Screening Survey 2023.韩国男性前列腺癌筛查的决定因素:一项基于2023年韩国国家癌症筛查调查的全国性研究
Cancer Res Treat. 2025 Apr;57(2):539-546. doi: 10.4143/crt.2024.879. Epub 2024 Oct 29.
2
The Short- and Long-Term Anticipation of Prostate Cancer Incidence in Korea: Based on Social Aging Trends and Prostate-Specific Antigen Testing Rate during the Last Decade.韩国前列腺癌发病率的短期和长期预测:基于过去十年的社会老龄化趋势和前列腺特异性抗原检测率
Cancers (Basel). 2024 Jan 24;16(3):503. doi: 10.3390/cancers16030503.
3

本文引用的文献

1
Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study.在一个社会对前列腺癌认知有限的国家,重复前列腺特异性抗原筛查对治疗模式的影响:韩国全国观察性研究。
Investig Clin Urol. 2021 May;62(3):282-289. doi: 10.4111/icu.20200302. Epub 2021 Mar 29.
2
Epidemiology and genomics of prostate cancer in Asian men.亚洲男性前列腺癌的流行病学和基因组学。
Nat Rev Urol. 2021 May;18(5):282-301. doi: 10.1038/s41585-021-00442-8. Epub 2021 Mar 10.
3
Relationship between Socioeconomic Status and Prevalent Prostate Cancer in the South Korea.
The epidemiology of male lower urinary tract symptoms associated with benign prostatic hyperplasia: Results of 20 years of Korean community care and surveys.
与良性前列腺增生相关的男性下尿路症状的流行病学:20 年韩国社区护理和调查结果。
Investig Clin Urol. 2024 Jan;65(1):69-76. doi: 10.4111/icu.20230249.
4
Trends of stratified prostate cancer risk in a single Korean province from 2003 to 2021: A multicenter study conducted using regional training hospital data.2003 年至 2021 年韩国某一省内前列腺癌风险的分层趋势:一项使用地区培训医院数据进行的多中心研究。
Investig Clin Urol. 2023 Mar;64(2):140-147. doi: 10.4111/icu.20220317.
5
Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2.多西他赛通过锌指同源物2增强子的表观遗传基因调控增强肿瘤坏死因子相关凋亡诱导配体介导的前列腺癌细胞凋亡。
World J Mens Health. 2023 Jul;41(3):649-658. doi: 10.5534/wjmh.220073. Epub 2023 Jan 1.
韩国社会经济地位与前列腺癌患病率之间的关系。
Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3137-3144. doi: 10.31557/APJCP.2019.20.10.3137.
4
Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.前列腺癌筛查:历史、证据、争议以及个体化筛查的未来展望。
Int J Urol. 2019 Oct;26(10):956-970. doi: 10.1111/iju.14039. Epub 2019 Jun 10.
5
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.前列腺癌筛查中前列腺特异性抗原(PSA)检测的系统评价和荟萃分析。
BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519.
6
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.前列腺癌筛查:美国预防服务工作组推荐声明。
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
7
Reevaluating PSA Testing Rates in the PLCO Trial.重新评估前列腺、肺、结直肠癌和卵巢癌筛查试验(PLCO)中的前列腺特异性抗原(PSA)检测率
N Engl J Med. 2016 May 5;374(18):1795-6. doi: 10.1056/NEJMc1515131.
8
Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.韩国、白种人和非裔美国男性前列腺癌侵袭性的差异:一项前列腺癌根治术的回顾性队列研究。
Urol Oncol. 2016 Jan;34(1):3.e9-14. doi: 10.1016/j.urolonc.2015.08.004. Epub 2015 Sep 4.
9
Korean prostate cancer patients have worse disease characteristics than their American counterparts.韩国前列腺癌患者的疾病特征比美国患者更差。
Asian Pac J Cancer Prev. 2013;14(11):6913-7. doi: 10.7314/apjcp.2013.14.11.6913.
10
Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening.基于前列腺特异性抗原的人群筛查后中年前列腺癌患者的临床症状和预后趋势。
Prostate Int. 2013;1(2):65-8. doi: 10.12954/PI.12017. Epub 2013 Jun 30.